Clinical trial

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

NCT05751798

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-12-20

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2022-12-20Date precision: day

Registry last updated2026-06-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Advanced Tumorunresolved

Lymphomaunresolved

NSCLC (Non-small Cell Lung Cancer)unresolved

Interventions

Part A: OSE-279 100mgDRUG

Part A: OSE-279 300mgDRUG

Part A: OSE-279 600mgDRUG

Part B: OSE-279 600 mg and OSE2101DRUG

Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positiveDRUG

Part C: OSE-279 600 mg - HLA-A2 positifDRUG

Part C: OSE-279 600 mg - HLA-A2 negativeDRUG

Sponsors & collaborators

OSE Immunotherapeuticslead sponsor

Mapped research locations

ParisFrance1 ToulouseFrance1 LyonFrance1 MálagaSpain1 RennesFrance1 VillejuifFrance1 A CoruñaSpain1 Saint-HerblainFrance1 EdegemBelgium1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05751798 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.